Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium

DSpace/Manakin Repository

Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium

Show simple item record

dc.contributor.author Tefferi, A
dc.contributor.author Abdel-Wahab, O
dc.contributor.author Cervantes, F
dc.contributor.author Crispino, J D
dc.contributor.author Finazzi, G
dc.contributor.author Girodon, F
dc.contributor.author Gisslinger, H
dc.contributor.author Gotlib, J
dc.contributor.author Kiladjian, J-J
dc.contributor.author Licht, J D
dc.contributor.author Odenike, O
dc.contributor.author Pardanani, A
dc.contributor.author Silver, R T
dc.contributor.author Solary, E
dc.contributor.author Mughal, T
dc.contributor.author Mullally, Ann
dc.contributor.author Levine, R L
dc.date.accessioned 2012-04-19T19:27:17Z
dc.date.issued 2011
dc.identifier.citation Tefferi, A.O., Abdel-Wahab, F. Cervantes, J.D. Crispino, G. Finazzi, F. Girodon, H. Gisslinger, et al. 2011. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: proceedings from the 5th international post-ash symposium. Blood Cancer Journal 1(3): e7. en_US
dc.identifier.issn 2044-5385 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8603493
dc.description.abstract Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCR-ABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7–8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presented at the 2010 ASH meeting, were discussed among recognized authorities in the field. The current paper summarizes the proceedings of this meeting in BCR-ABL1-negative MPN. We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inhibitors, pomalidomide, everolimus, interferon-α, midostaurin and cladribine. In addition, the new ‘Dynamic International Prognostic Scoring System (DIPSS)-plus' prognostic model for primary myelofibrosis (PMF) and the clinical relevance of distinguishing essential thrombocythemia from prefibrotic PMF are discussed. en_US
dc.language.iso en_US en_US
dc.publisher Nature Publishing Group en_US
dc.relation.isversionof doi:10.1038/bcj.2011.4 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255279/pdf/ en_US
dash.license LAA
dc.subject myeloproliferative en_US
dc.subject myelofibrosis en_US
dc.subject polycythemia en_US
dc.subject thrombocythemia en_US
dc.subject mastocytosis en_US
dc.title Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Blood Cancer Journal en_US
dash.depositing.author Mullally, Ann
dc.date.available 2012-04-19T19:27:17Z

Files in this item

Files Size Format View
3255279.pdf 431.3Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters